Arca
Skip to content
Tools
Tools

Label Changes: Gazyva (obinutuzumab)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Gazyva label DailyMed has published, from Genentech, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 20
  • Sections changed, version 22 to 23: 8

What changed from version 22 to version 23

Dec 23, 2025 to Oct 6, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 44 words added
  2. Dosage and administrationChanged · 596 words added, 15 removed
  3. Warnings and precautionsChanged · 281 words added, 45 removed
  4. Adverse reactionsChanged · 416 words added, 15 removed
  5. Use in specific populationsChanged · 148 words added, 15 removed
  6. Clinical pharmacologyChanged · 252 words added, 49 removed
  7. Clinical studiesChanged · 933 words added, 11 removed
  8. Untitled sectionChanged · 1 word added, 1 removed

Indications and usage

Changed44 words added
7 unchanged lines
GAZYVA is indicated for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
1.4 Childhood-Onset Idiopathic Nephrotic Syndrome (INS)
GAZYVA is indicated to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.

Dosage and administration

Changed596 words added, 15 removed
1 unchanged line
2.1 Important Dosing Information
Premedicate before each infusion [see Dosage and Administration (2.46)].
Provide prophylactic hydration and anti-hyperuricemics to patients at high risk of tumor lysis syndrome [see Dosage and Administration (2.46) and Warnings and Precautions (5.45)].
Administer only as an intravenous infusion through a dedicated line [see Dosage and Administration (2.68)].
Do not administer as an intravenous push or bolus.
37 unchanged lines
Dose number | Timing of treatment | Dose of GAZYVA | Rate of infusion
1 | Initial infusion | 1,000 mg | Administer at a rate of 50 mg/hr. The rate of infusion can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. For management of IRRs that occur during infusion, see Dosage Modifications for Adverse Reactions (2.67) .
2 | Week 2 (two weeks after Dose 1) | 1,000 mg | Administer at a rate of 100 mg/hr. The rate of infusion can be escalated at a rate of 100 mg/hr every 30 minutes to a maximum of 400 mg/hr.
2 unchanged lines
5 and thereafter | Every 6 months | 1,000 mg
Patients who do not experience Grade ≥ 3 or higher infusion related reactions during the previous infusion may receive GAZYVA over approximately 90 minutes from Dose 2 onwards (see Table 5), with continued premedication.
Table 5 Dose and Infusion Rate for a 90-Minute Infusion of GAZYVA in Adults with Active Lupus Nephritis
3 unchanged lines
If a planned dose of GAZYVA is missed, it should be administered as soon as possible – do not wait until the next planned dose. The schedule of administration should be adjusted to maintain the appropriate interval between doses.
2.5 Recommended Dosage for Childhood-Onset Idiopathic Nephrotic Syndrome
The recommended dose of GAZYVA in patients weighing 45 kg or more who are in complete remission is 1,000 mg administered intravenously according to Table 6. For patients weighing less than 45 kg, the recommended dose is 20 mg/kg administered intravenously according to Table 6.
Data are insufficient to provide dosing recommendations for patients who relapse during or after treatment with GAZYVA.
Table 6 Dose and Infusion Rate of GAZYVA for patients with Childhood-Onset Idiopathic Nephrotic Syndrome
Dose number | Timing of treatment | Patient Weight | Dose of GAZYVA | Rate of infusion
1 | Initial infusion | 45 kg or more | 1,000 mg | Administer at a rate of 12.5 mL/hr. The rate of infusion can be escalated at a rate of 12.5 mL/hr every 30 minutes to a maximum of 100 ml/hr. For management of IRRs that occur during infusion, see Dosage Modifications for Adverse Reactions (2.7) .
Less than 45 kg | 20 mg/kg
2 | Week 2 (two weeks after Dose 1) | 45 kg or more | 1,000 mg | Administer at a rate of 25 mL/hr. The rate of infusion can be escalated at a rate of 25 mL/hr every 30 minutes to a maximum of 100 mL/hr. If a clinically significant infusion-related reaction (IRR) occurred during the first infusion, start the subsequent scheduled infusion at no more than half the rate at which the IRR occurred (e.g., if the IRR occurred at 50 mL/hour, start the next infusion at 25 mL/hour).
Less than 45 kg | 20 mg/kg
3 | Week 24 | 45 kg or more | 1,000 mg
Less than 45 kg | 20 mg/kg
4 | Week 26 (two weeks after Dose 3) | 45 kg or more | 1,000 mg
Less than 45 kg | 20 mg/kg
For patients receiving concomitant oral corticosteroids, the corticosteroids should be tapered off after initiating GAZYVA at the discretion of the healthcare provider [see Clinical Studies (14.4)].
If a planned dose of GAZYVA is missed, it should be administered as soon as possible – do not wait until the next planned dose. The schedule of administration should be adjusted to maintain the appropriate interval between doses.
2.56 Recommended Premedication and Prophylactic Medications
Infusion-Related Reactions
Premedication to reduce the risk of IRRs is outlined in Table 67 [see Warnings and Precautions (5.3)].
Hypotension may occur during GAZYVA intravenous infusions. Consider withholding antihypertensive treatments for 12 hours prior to and throughout each GAZYVA infusion and for the first hour after administration [see Warnings and Precautions (5.3)].
Table 67 Premedication for GAZYVA Infusion to Reduce Infusion-Related Reactions
Indication/Cycle/Day of Treatment | Patients requiring premedication | Premedication | Administration
1 unchanged line
CLL Cycle 1 Days 1 and 2 FL Cycle 1 Day 1 | All patients | Intravenous glucocorticoid: 20 mg dexamethasone or 80 mg methylprednisolone , | Completed at least 1 hour prior to GAZYVA infusion.
650– to 1,000 mg acetaminophen | At least 30 minutes before GAZYVA infusion.
anti-histamine (e.g., 50 mg diphenhydramine)
CLL or FL All subsequent infusions | All patients | 650– to 1,000 mg acetaminophen | At least 30 minutes before GAZYVA infusion.
Patients with an IRR (Grade 1-2) with the previous infusion | 650– to 1,000 mg acetaminophen | At least 30 minutes before GAZYVA infusion.
anti-histamine (e.g., 50 mg diphenhydramine)
Patients with a Grade 3 IRR with the previous infusion OR with a lymphocyte count > 25 × 109/L prior to next treatment | Intravenous glucocorticoid: 20 mg dexamethasone or 80 mg methylprednisolone | Completed at least 1 hour prior to GAZYVA infusion.
650– to 1,000 mg acetaminophen | At least 30 minutes before GAZYVA infusion.
anti-histamine (e.g., 50 mg diphenhydramine)
LN | All patients | Intravenous glucocorticoid (80 mg methylprednisolone) | Completed between 30 and 60 minutes prior to GAZYVA infusion Starting from Dose 6, intravenous corticosteroid should only be administered to patients who have experienced an IRR in the prior infusion
650– to 1,000 mg acetaminophen
anti-histamine (e.g., 50 mg diphenhydramine)
Childhood-Onset INS | All patients | Intravenous glucocorticoid: Administer 80 mg methylprednisolone to patients weighing 45 kg or more. For patients weighing less than 45 kg, administer methylprednisolone 1.5 mg/kg | Completed between 30 and 60 minutes prior to GAZYVA infusion
15 mg/kg of body weight acetaminophen (maximum 1,000 mg)
Antihistamine (e.g. 0.5 to 1 mg/kg of body weight or maximum 50 mg diphenhydramine)
Tumor Lysis Syndrome Prophylaxis
Patients with high tumor burden, high circulating absolute lymphocyte counts (greater than 25 × 109/L) or renal impairment are considered at risk of tumor lysis syndrome and should receive prophylaxis. Premedicate with anti-hyperuricemics (e.g., allopurinol or rasburicase) and ensure adequate hydration prior to start of GAZYVA therapy. Continue prophylaxis prior to each subsequent GAZYVA infusion, as needed [see Warnings and Precautions (5.45)].
Antimicrobial Prophylaxis
Patients with Grade 3 to 4 neutropenia lasting more than one week are strongly recommended to receive antimicrobial prophylaxis until resolution of neutropenia to Grade 1 or 2. Consider antiviral and antifungal prophylaxis for patients with severe and long lasting (> 1 week) neutropenia.
2.67 Dosage Modifications for Adverse Reactions
Infusion-Related Reactions
1 unchanged line
Grade 4 (life-threatening): Stop infusion immediately and permanently discontinue GAZYVA.
Grade 3 (severe): Interrupt infusion and manage symptoms. For patients who experience Grade 3 IRRs during standard infusion, upon resolution of symptoms, consider restarting GAZYVA infusion at no more than half the previous rate (the rate being used at the time that the IRR reaction occurred) for 30 minutes, and if patientpatients doesdo not experience any further IRR symptoms, the infusion rate escalation may resume at the increments and intervals as appropriate for the treatment cycle dose. Permanently discontinue treatment if patients experience a Grade 3 or higher IRR at rechallenge. For patients with FL who experience Grade 3 IRRs during the approximately 90-minute infusion, upon resolution of symptoms, the infusion can be restarted at no more than half the previous rate (the rate being used at the time that the IRR occurred) and not greater than 400 mg/hr. Administer subsequent infusions at the standard rate. Permanently discontinue treatment if patients experience a Grade 3 or higher IRR at rechallenge. For patients with CLL only, the Day 1 infusion rate may be increased back up to 25 mg/hr after 1 hour but not increased further.
Grade 1–2 (mild to moderate): Reduce infusion rate or interrupt infusion and manage symptoms. Upon resolution of symptoms, continue or resume GAZYVA infusion, and if patient does not experience any further IRR symptoms, infusion rate escalation may resume at the increments and intervals as appropriate for the treatment cycle dose. For patients with CLL only, the Day 1 infusion rate may be increased back up to 25 mg/hr after 1 hour but not increased further. For patients with LN or childhood-onset INS, reduce infusion rate to half the rate that was used at the time of the reaction and treat symptoms. Upon resolution of symptoms, the infusion should be kept at the reduced rate for an additional 30 minutes. If no further symptoms of IRR, infusion rate escalation may resume at the increments and intervals as appropriate for the treatment dose.
Other Adverse Reactions
Consider treatment interruption if patients experience an infection, Grade 3 or 4 cytopenia, or Grade 2 or higher non-hematologic toxicity.
2.78 Preparation and Administration
Preparation
2 unchanged lines
Use a sterile needle and syringe to prepare GAZYVA.
Dilute into a 0.9% Sodium Chloride Injection, USP PVC or non-PVC polyolefin infusion bag. Chronic Lymphocytic Leukemia Preparation of solution for infusion on day 1 (100 mg) and day 2 (900 mg) of Cycle 1: Prepare day 1 (100 mg) and day 2 (900 mg) infusion bags at the same time using one vial (1,000 mg/40 mL) on day 1. Withdraw 40 mL of GAZYVA solution from the vial. Dilute 4 mL (100 mg) of GAZYVA into a 100 mL 0.9% Sodium Chloride Injection, USP infusion bag for immediate administration. Dilute the remaining 36 mL (900 mg) into a 250 mL 0.9% Sodium Chloride Injection, USP infusion bag at the same time for use on day 2 and store in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours. After allowing the diluted bag to come to room temperature, use immediately. Clearly label each infusion bag. Preparation of solution for infusion on day 8 and 15 of Cycle 1 and day 1 of Cycles 2–6: Withdraw 40 mL of GAZYVA solution from the vial. Dilute 40 mL (1,000 mg) into a 250 mL 0.9% Sodium Chloride Injection, USP infusion bag. Follicular Lymphoma and, Active Lupus Nephritis and Childhood-Onset Idiopathic Nephrotic Syndrome patients weighing 45 kg or more Preparation of solution for infusion: Withdraw 40 mL of GAZYVA solution from the vial. Dilute 40 mL (1,000 mg) into a 250 mL 0.9% Sodium Chloride Injection, USP infusion bag. Childhood-Onset Idiopathic Nephrotic Syndrome patients weighing less than 45 kg Preparation of solution for infusion: Calculate the dose (mg) based on the patient's body weight and the total volume of GAZYVA solution required. Final GAZYVA solution to add to the infusion bag (mL) = Patient weight (kg) x 20 mg/kg × 40 mL 1,000 mg Withdraw a volume equal to the required GAZYVA solution from a 250 mL infusion bag of 0.9% Sodium Chloride Injection, USP and discard it. Add the required volume of GAZYVA solution slowly into the 0.9% Sodium Chloride Injection, USP infusion bag. Discard any unused portion of GAZYVA solution remaining in the vial.
Mix diluted solution by gentle inversion. Do not shake or freeze.
9 unchanged lines

Warnings and precautions

Changed281 words added, 45 removed
9 unchanged lines
5.3 Infusion-Related Reactions
GAZYVA can cause severe and life-threatening infusion-related reactions (IRRs). Sixty-five percent of patients with CLL experienced a reaction to the first 1,000 mg of GAZYVA infused. Thirty-seven percent of patients with relapsed or refractory NHL and 60% of patients with previously untreated NHL experienced a reaction on Day 1 of GAZYVA infusion. In patients with CLL and NHL , IRRs have occurred within 24 hours of receiving GAZYVA. IRRs can also occur with subsequent infusions. Symptoms may include hypotension, tachycardia, dyspnea, and respiratory symptoms (e.g., bronchospasm, larynx and throat irritation, wheezing, laryngeal edema). The most frequently reported IRR symptoms in patients with CLL and NHL include nausea, fatigue, chest discomfort, dyspnea, dizziness, vomiting, diarrhea, rash, hypertension, hypotension, flushing, headache, pyrexia, and chills [see Adverse Reactions (6.1)].
In patients with LN, IRRs occurred predominantly during infusion of the first 1,000 mg. IRRs were generally mild to moderate and could be managed by the slowing or temporarily halting the infusion [see Dosage and Administration (2.67)]. Severe and life-threatening IRRs requiring symptomatic treatment were also reported. The most common IRR signs or symptoms reported in the REGENCY study included headache, nausea and vomiting. In the NOBILITY study, the most common IRR symptoms were pyrexia and tachycardia [see Adverse Reactions (6.21)].
In patients with childhood-onset INS, IRRs occurred predominantly during the first infusion of GAZYVA. All IRRs were mild to moderate and could be managed by slowing or temporarily halting the infusion [see Dosage and Administration (2.7)]. The most common IRR signs or symptoms reported in the INSHORE study were pyrexia, vomiting, and nausea [see Adverse Reactions (6.1)].
Premedicate patients with acetaminophen, anti-histamine, and a glucocorticoid [see Dosage and Administration (2.46)]. Closely monitor patients during the entire infusion. Reduce infusion rate, interrupt infusion or permanently discontinue GAZYVA for IRRs based on severity [see Dosage and Administration (2.57)]. Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, and/or oxygen) for IRRs as needed.
For patients with preexisting cardiac or pulmonary conditions, monitor more frequently throughout the infusion and the post-infusion period since they may be at greater risk of experiencing more severe reactions. Hypotension may occur as part of the IRR to GAZYVA. Consider withholding antihypertensive treatments for 12 hours prior to, during each GAZYVA infusion, and for the first hour after administration until blood pressure is stable. For patients at increased risk of hypertensive crisis, consider the benefits versus the risks of withholding their antihypertensive medication as is suggested here.
4 unchanged lines
Tumor lysis syndrome (TLS), including fatal cases, has been reported in patients with CLL and NHL receiving GAZYVA. Patients with high tumor burden, high circulating lymphocyte count (> 25 × 109/L) or renal impairment are at greater risk for TLS.
In patients with CLL and NHL at risk for TLS, administer appropriate tumor lysis prophylaxis with anti-hyperuricemics (e.g., allopurinol or rasburicase) and hydration prior to the infusion of GAZYVA [see Dosage and Administration (2.46)]. During the initial days of GAZYVA treatment, monitor the laboratory parameters of patients considered at risk for TLS. For treatment of TLS, correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated. TLS is not identified as a risk in LN or childhood-onset INS.
5.6 Serious, Including Fatal, Infections
3 unchanged lines
In 40 patients who crossed-over from placebo to GAZYVA and standard therapy at Week 76 in the REGENCY study and patients who continued treatment with GAZYVA and standard therapy, including additional treatment after Week 76, the EAIR of Grade 3-5 infections for the GAZYVA arm was 9.0 per 100 patient-years while the EAIR of fatal infections for the GAZYVA arm was 1.8 per 100 patient-years.
Idiopathic Nephrotic Syndrome
In the INSHORE study, the incidence of Grade 3 (severe or medically significant) infections was 11% (5/44) in patients randomized to GAZYVA compared to 5% (2/41) in the mycophenolate mofetil (MMF) arm. The most frequently reported Grade 3 infection related to study treatment in the GAZYVA arm was pneumonia (2/44 patients, 5%) [see Adverse Reactions (6.1)]. No Grade 4 or Grade 5 (life-threatening or fatal) infections were reported in either arm.
CLL and FL
2 unchanged lines
5.7 Neutropenia
Severe and life-threatening neutropenia, including febrile neutropenia, has been reported during treatment with GAZYVA. Monitor patients with Grade 3 to 4 neutropenia frequently with regular laboratory tests until resolution. Anticipate, evaluate, and treat any symptoms or signs of developing infection. Consider dose delays for Grade 3 or 4 neutropenia. Consider administration of granulocyte colony-stimulating factorsfactor (GCSF) in patients with Grade 3 or 4 neutropenia.
Neutropenia can also be of late onset (occurring more than 28 days after completion of treatment) and/or prolonged (lasting longer than 28 days). Patients with severe and long lasting (> 1 week) neutropenia are strongly recommended to receive antimicrobial prophylaxis until resolution of neutropenia to Grade 1 or 2. Consider antiviral and antifungal prophylaxis.
6 unchanged lines
5.10 Immunization
The safety and efficacy of immunization with live or attenuated viral vaccines during or following GAZYVA therapy have not been studied. Immunization with live virus vaccines is not recommended during treatment with GAZYVA and until B-cell recovery.
Because of its mechanism of action, GAZYVA may interfere with the immune responses to vaccines and increase the risk of infection from live vaccines. The safety and efficacy of immunization with live or attenuated viral vaccines during or following GAZYVA therapy have not been studied. Immunization with live virus vaccines is not recommended during treatment with GAZYVA, and until B-cell recovery (CD19+ B-cell counts ≥ lower limit of normal or return to baseline).
In patients with childhood-onset INS, administer all age-appropriate live vaccines at least 28 days prior to initiation of GAZYVA. Do not administer live virus vaccines during treatment or until B-cell recovery is confirmed. Monitor B-cell counts prior to resuming any live vaccination. [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.2) ].
5.11 Embryo-Fetal Toxicity
1 unchanged line

Adverse reactions

Changed416 words added, 15 removed
16 unchanged lines
Adverse reactions in ≥ 10% of patients in the GAZYVA containing arm were infusion-related reactions, neutropenia, thrombocytopenia, and diarrhea. The most common Grade 3 to 4 adverse reactions (incidence ≥ 10%) in the GAZYVA containing arm were neutropenia, infusion-related reactions, and thrombocytopenia.
Table 78 Adverse Reactions (Incidence ≥ 5% and ≥ 2% Greater in the GAZYVA Arm) in Patients with CLL (Stage 2)
Body System Adverse Reactions | GAZYVA + Chlorambucil n = 336 | Rituximab product + Chlorambucil n = 321
13 unchanged lines
Urinary Tract Infection | 5 | 1 | 2 | < 1
Table 89 Post-Baseline Laboratory Abnormalities (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm) in Patients with CLL (Stage 2)
Laboratory Abnormalities | GAZYVA + Chlorambucil n = 336 | Rituximab product + Chlorambucil n = 321
19 unchanged lines
Dose modification due to adverse reactions occurred in 50% of the GAZYVA arm and 42% of the control arm, and discontinuation of any study drug due to adverse reactions occurred in 20% and 17%, respectively.
Table 910 presents selected adverse reactions in GADOLIN. The most common adverse reactions (incidence ≥ 20%) in GAZYVA recipients included infusion-related reactions, fatigue, neutropenia, cough, upper respiratory tract infections, and musculoskeletal pain.
Table 910 Adverse Reactions (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm) in Patients with Relapsed or Refractory NHL (GADOLIN)
Body System Adverse Reactions , | GAZYVA + Bendamustine followed by GAZYVA monotherapy n = 204 | Bendamustine n = 203
34 unchanged lines
During GAZYVA monotherapy (158 patients), adverse reactions in ≥ 10% of patients included upper and lower respiratory tract infections, cough, neutropenia, musculoskeletal pain, fatigue, diarrhea, rash, and urinary tract infection.
Table 1011 presents selected new or worsening laboratory abnormalities in the GADOLIN trial.
Table 1011 New or Worsening Laboratory Abnormalities (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm ) in Patients with Relapsed or Refractory NHL (GADOLIN)
Laboratory Abnormalities | GAZYVA + Bendamustine followed by GAZYVA monotherapy n = 204 | Bendamustine n = 203
17 unchanged lines
During combination therapy, 93% of patients received all treatment cycles in the GAZYVA arm, and 92% received all treatment cycles in the rituximab product arm. Of the responding patients who began monotherapy with GAZYVA or rituximab product, 76% and 73%, respectively, completed the full course. Dose modification due to adverse reactions occurred in 74% of the GAZYVA arm and 63% of the rituximab product arm throughout study treatment, and discontinuation of any study drug due to adverse reactions occurred in 18% and 15%, respectively.
Throughout treatment and follow-up, the most common adverse reactions (incidence ≥ 20%) observed at least 2% more in the GAZYVA arm included infusion-related reactions, neutropenia, upper respiratory tract infections, constipation and diarrhea (Table 1112). Neutropenia, infusion-related reactions, febrile neutropenia and thrombocytopenia were the most common Grade 3 to 5 adverse reactions (incidence ≥ 5%) observed more frequently in the GAZYVA arm.
Table 1112 Adverse Reactions (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm) in Patients with Previously Untreated NHL (GALLIUM)
Body System Adverse Reactions , | GAZYVA + chemotherapy followed by GAZYVA monotherapy n = 691 | Rituximab product + chemotherapy followed by rituximab product monotherapy n = 694
36 unchanged lines
During the monotherapy period, the common adverse reactions (incidence ≥ 10%) observed at least 2% more with GAZYVA were upper respiratory tract infection (40%), cough (23%), musculoskeletal pain (20%), neutropenia (19%), and herpesvirus infection (13%).
Table 1213 summarizes treatment-emergent laboratory abnormalities during treatment and follow-up. The Grade 3 to 4 abnormalities reported at least 2% more in the GAZYVA arm were lymphopenia, leukopenia, neutropenia, thrombocytopenia, and hyperuricemia. Patients in the GAZYVA arm, as compared to the rituximab product arm, had higher incidences of Grade 4 neutropenia (38% vs. 30%, respectively), Grade 4 lymphopenia (33% vs. 22%), and Grade 4 leukopenia (17% vs. 12%).
Table 1213 New or Worsening Laboratory Abnormalities (Incidence ≥ 10% and ≥ 2% Greater in the GAZYVA Arm) in Patients with Previously Untreated NHL (GALLIUM)
Laboratory Abnormalities | GAZYVA+ chemotherapy followed by GAZYVA monotherapy n = 691 | Rituximab product + chemotherapy followed by rituximab product monotherapy n = 694
26 unchanged lines
The most common serious adverse reactions in the GAZYVA arm were: COVID-19 (11 patients [5.5%]), pneumonia (9 patients [4.5%]), neutropenia (7 patients [3.5%]), urinary tract infections (5 patients [2.5%]) and infusion-related reactions (1 patient [0.5%]). No serious adverse reactions were reported for bronchitis, herpes simplex and upper respiratory tract infections. Two fatal adverse reactions of COVID-19 were reported in the GAZYVA arm.
Adverse reaction rates are presented in Table 1314.
Table 1314 Adverse Reactions in Adults with Active Lupus Nephritis Treated with GAZYVA Versus Placebo (≥ 2% Greater in the GAZYVA Arm) in REGENCY and NOBILITY Studies
Body System Adverse Reactions | GAZYVA + standard therapy n = 200 | Placebo + standard therapy n = 193
11 unchanged lines
Neutropenia | 14 | 7 | 6 | 0.5
Childhood-Onset Idiopathic Nephrotic Syndrome
The data described in Table 15 reflect exposure to GAZYVA administered intravenously in patients with childhood-onset INS in the INSHORE study (NCT05627557). In INSHORE, 44 patients received GAZYVA, of which 41 patients were 4 to 18 years of age [see Clinical Studies (14.4)]. Adverse event severity was graded as Grades 1 to 5 defined as mild (1), moderate (2), severe (3), life-threatening (4), and fatal (5).
The most common adverse reactions (incidence ≥ 10% in the GAZYVA arm) are shown in Table 15. There were no Grade 5 adverse reactions in INSHORE.
Table 15 Adverse Reactions in Patients with Childhood-Onset Idiopathic Nephrotic Syndrome Treated with GAZYVA Versus Mycophenolate Mofetil (≥ 10% in the GAZYVA Arm) in the INSHORE study
Body System Adverse Drug Reactions | GAZYVA n = 44 | MMF n = 41
All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%)
NA: Not Applicable
Infections and Infestations
Upper Respiratory Tract Infection | 59 | 2 | 63 | 2
Ear Infection | 32 | 2 | 15 | 0
Pneumonia | 25 | 9 | 5 | 0
Influenza | 20 | 0 | 10 | 0
Bronchitis | 14 | 2 | 5 | 0
COVID-19 | 14 | 0 | 12 | 0
Conjunctivitis | 14 | 0 | 7 | 0
Urinary Tract Infection | 11 | 0 | 0 | 0
Injury, Poisoning and Procedural Complications
Infusion Related Reaction | 36 | 0 | NA | NA
Blood and Lymphatic System Disorders
Neutropenia | 18 | 16 | 2 | 2
Specific Adverse Reactions
17 unchanged lines
In the REGENCY study, most common IRR signs or symptoms included headache, nausea and vomiting. In the NOBILITY study, the most common IRR symptoms were pyrexia and tachycardia.
Childhood-Onset Idiopathic Nephrotic Syndrome
In the INSHORE study, all IRRs were Grade 1-2 (mild or moderate) and predominately occurred during/after the first infusion [see Table 15 and Warnings and Precautions (5.3)]. IRRs requiring GAZYVA infusion interruption, rate reduction, or stoppage occurred in 23% of patients. The most common IRR signs or symptoms included pyrexia, vomiting and nausea.
Neutropenia
Chronic Lymphocytic Leukemia
The incidence of neutropenia reported as an adverse reaction in CLL11 was 38% in the GAZYVA treated arm and 32% in the rituximab product treated arm, with the incidence of serious adverse reactions being 1% and < 1%, respectively (Table 79). Cases of late-onset neutropenia (occurring 28 days after completion of treatment or later) were 16% in the GAZYVA treated arm and 12% in the rituximab product treated arm.
Non-Hodgkin Lymphoma
2 unchanged lines
Lupus Nephritis
In the pooled REGENCY and NOBILITY studies, neutropenia and related adverse reactions (i.e., leukopenia, lymphopenia, lymphocyte count decreased, febrile neutropenia, and neutrophil count decreased) were reported in 14% of patients in the GAZYVA arm versus 6% of patients in the placebo arm. Grade 3-4 neutropenia was reported in 7% of patients treated with GAZYVA versus 0.5% of patients in the placebo arm. Neutropenia and related adverse reactions resolved/improved spontaneously or with use of granulocyte colony-stimulating factorsfactor in 96% of patients [see Warnings and Precautions (5.7)].
Childhood-Onset Idiopathic Nephrotic Syndrome
In the INSHORE study, the majority of neutropenia and related adverse reactions (i.e., neutrophil count decreased and agranulocytosis) in both arms were Grade 3 or 4 (severe or life-threatening or due to neutrophil count < 1000 cells/µL; see Table 15). The majority of neutropenia and related events resolved/improved spontaneously and one event resolved with the use of granulocyte colony-stimulating factor [see Warnings and Precautions (5.7)].
Infection
7 unchanged lines
In the pooled REGENCY and NOBILITY studies, infections were reported in 72% of patients in the GAZYVA arm versus 62% of patients in the placebo arm. The most frequently reported infections were upper and lower respiratory tract infections. Grade 3-5 infections were reported in 11% of patients in the GAZYVA arm versus 10% of patients in the placebo arm. Fatal infection events were reported in 1% of patients in the GAZYVA arm versus 0.5% of patients in the placebo arm [see Warnings and Precautions (5.6)].
Childhood-Onset Idiopathic Nephrotic Syndrome
In the INSHORE study, infections were reported in 89% of patients in the GAZYVA arm compared to 76% in the MMF arm. The most frequently reported infections are shown in Table 15 [see Warnings and Precautions (5.6)].
Thrombocytopenia
Chronic Lymphocytic Leukemia
The overall incidence of thrombocytopenia reported as an adverse reaction was higher in the GAZYVA treated arm (14%) compared to the rituximab product treated arm (7%), with the incidence of Grade 3 to 4 events being 10% and 3%, respectively (Table 78). The difference in incidences between the treatment arms is driven by events occurring during the first cycle. The incidence of thrombocytopenia (all grades) in the first cycle was 11% in the GAZYVA and 3% in the rituximab product treated arms, with Grade 3 to 4 rates being 8% and 2%, respectively. Four percent of patients in the GAZYVA treated arm experienced acute thrombocytopenia (occurring within 24 hours after the GAZYVA infusion).
The overall incidence of hemorrhagic events and the number of fatal hemorrhagic events were similar between the treatment arms, with 3 in the rituximab product and 4 in the GAZYVA treated arms. However, all fatal hemorrhagic events in patients treated with GAZYVA occurred in Cycle 1.
22 unchanged lines

Use in specific populations

Changed148 words added, 15 removed
8 unchanged lines
Fetal/Neonatal Adverse Reactions
GAZYVA is likely to cause fetal B-cell depletion (see Data). Avoid administering live vaccines to neonates and infants exposed to GAZYVA in utero until B-cell recovery occurs [see Warnings and Precautions (5.11), Use in Specific Populations (8.4) and Clinical Pharmacology (12.2)].
Data
12 unchanged lines
8.4 Pediatric Use
The safety and effectiveness of GAZYVA for reducing the risk of relapse in steroid dependent or frequently relapsing childhood-onset INS have been established in pediatric patients aged 2 years and older. Use of GAZYVA for this indication is supported by evidence from an adequate and well controlled trial that enrolled 81 pediatric patients aged 2 years and older [see Adverse Reactions (6.1), and Clinical Studies (14.4)]. The safety and effectiveness of GAZYVA for reducing the risk of relapse in pediatric patients less than 2 years of age with steroid dependent or frequently relapsing childhood-onset INS have not been established.
The safety and effectiveness of GAZYVA in pediatric patients have not been established.
The safety and efficacy of GAZYVA in pediatric patients with chronic lymphocytic leukemia, follicular lymphoma, or active lupus nephritis have not been established.
8.5 Geriatric Use
4 unchanged lines
Of the 691 patients in GALLIUM treated with GAZYVA plus chemotherapy as first-line therapy, 33% were 65 and over, while 7% were 75 and over. Of patients 65 and over, 63% experienced serious adverse reactions and 26% experienced adverse reactions leading to treatment withdrawal, while in patients under 65, 43% experienced serious adverse reactions and 13% had an adverse reaction leading to treatment withdrawal. No clinically meaningful differences in efficacy were observed between these patients and younger patients in GALLIUM.
Lupus Nephritis
Lupus Nephritis and Childhood-Onset Idiopathic Nephrotic Syndrome
Clinical studies of GAZYVA in patients with active LN or childhood-onset INS did not include sufficient numbers of patients aged 65 years and older (1 patient and 0 patients, respectively) to determine whether they respond differently from younger adult patients.

Clinical pharmacology

Changed252 words added, 49 removed
4 unchanged lines
12.2 Pharmacodynamics
Chronic Lymphocytic Leukemia
In patients with CLL, GAZYVA caused CD19 B-cell depletion (defined as CD19 B cell counts < 0.07 × 109/L). Initial CD19 B cell recovery was observed in some patients approximately 9 months after the last GAZYVA dose. At 18 months of follow-up, some patients remain B cell depleted.
Although the depletion of B cells in the peripheral blood is a measurable pharmacodynamic effect, it is not directly correlated with the depletion of B-cells in solid organs or in malignant deposits. B cell depletion has not been shown to be directly correlated to clinical response.
Lupus Nephritis
In patients with LN (REGENCY study), total peripheral CD19+ B cell levels below the defined threshold of 10 cells/µl were achieved in 99% of patients treated with GAZYVA by Week 4 after treatment initiation and remained below this threshold in 95% of patients at Week 76.
1 unchanged line
Treatment with GAZYVA led to improvements in complement (C3 and C4) and anti-double-stranded DNA antibodies (anti-dsDNA) by Week 4 and Week 12, respectively. These changes were sustained through Week 76.
In patients with low C3 at baseline, normalization of C3 levels occurred in 49% (by Week 12) and in 62% (by Week 76) of patients receiving GAZYVA compared to 33% and 29%, respectively, in the placebo group. In patients with low C4 at baseline, normalization of C4 levels occurred in 75% (by Week 12) and in 88% (by Week 76) of patients receiving GAZYVA compared to 55% and 55%, respectively, in the placebo group. Among patients with positive anti-dsDNA at baseline, 32% and 56% of patients treated with GAZYVA seroconverted by Week 4 and Week 76, respectively, compared with 16% and 16% of patients receiving placebo. The clinical relevance of the above mentioned pharmacodynamic biomarkers has not been established.
The clinical relevance of the above mentioned pharmacodynamic biomarkers has not been established.
Childhood-Onset Idiopathic Nephrotic Syndrome
In evaluable patients aged 4 years and older with childhood-onset INS who received GAZYVA in INSHORE, 100% (43 out of 43) were B-cell depleted (defined as CD19+ B cell counts < 10 cells/µL) at Week 4, and 95% (40 out of 42) remained depleted at Week 52. At Week 64, 73% (19 out of 26) remained B-cell depleted, and at Week 76, 36% (8 out of 22) remained depleted.
Mean counts of circulating B-cell subsets such as naïve B cells, memory B cells, and plasmablasts/plasma cells were 0 cells/µL by Week 2 after treatment initiation and remained low (near 0 cells/µL) through Week 52.
Cardiac Electrophysiology
1 unchanged line
12.3 Pharmacokinetics
The pharmacokinetic parameters of obinutuzumab after 100 mg on day 1 and 900 mg on day 2 of Cycle 1, 1,000 mg on day 8 and 15 of Cycle 1, and 1,000 mg on day 1 of Cycles 2-6 for CLL; after 1,000 mg on day 1, 8 and 15 of Cycle 1, 1,000 mg on day 1 of Cycles 2-6 or Cycles 2-8, and then 1,000 mg every 2 months for up to 2 years for NHL; 1,000 mg on day 1, week 2, 24, 26 and every 6 months for up to 76 Weeks for LN and childhood-onset INS are provided in Table 1416. The dosing regimen is within the linear pharmacokinetic behavior of obinutuzumab.
Table 1416 Obinutuzumab Pharmacokinetic Parameters
PK Measure | CLL | Relapsed or refractory FL | First line FL in combination with chemotherapy | LN | Childhood-Onset INS
GAZYVA + Bendamustine | GAZYVA + CHOP or CVP
Results are presented as geometric mean (% Coefficient of Variation).
Cmax, µg/mL | 466.3 (35) | 553.5 (32) | 513.4 (28) | 676.4 (30) | 463 (18) | 506 (17.7)
Ctrough, µg/mL | 192.5 (78) | 295 (56) | 255 (46) | 395 (44) | 0.91 (752) | 3.78 (282)
AUC, µg/mL*day | 8701 (51) | 11362 (41) | 10088 (35) | 10723 (37) | 8770 (38) | 13100 (26.7)
Distribution and Elimination
CLL and NHL
The elimination of obinutuzumab is comprised of a linear clearance pathway and a time-dependent non-linear clearance pathway. As GAZYVA treatment progresses, the impact of the time-dependent pathway diminishes in a manner suggesting target-mediated drug disposition (TMDD) and saturation of the TMDD at the end of the treatment cycle at the proposed clinical dosing regimen. The distribution and elimination parameters of obinutuzumab in patients with CLL and NHL are provided in Table 1517.
Table 1517 Distribution and Elimination Parameters of Obinutuzumab
| CLL | NHL
5 unchanged lines
Clearance, L/day | 0.11 (53) | 0.08 (41)
LN
LN and Childhood-Onset INS
The steady state clearance of obinutuzumab was approximately 0.13 L/day with a median elimination t1/2 of 22.4 days.
The steady state clearance of obinutuzumab in LN and childhood-onset INS was approximately 0.13 and 0.058 L/day, respectively, with a terminal elimination t1/2 of 22.4 and 29.5 days, respectively.
GAZYVA elimination comprises two parallel pathways, a linear clearance pathway and a non-linear clearance pathway, which changes as a function of time. The time-varying clearance decreases with time with an exponential decay coefficient, likely related to CD20 target reduction and proteinuria improvement over time in patients with elevated baseline proteinuria, and a time-independent clearance related to the endogenous catabolic processes of IgG.
Specific Populations
2 unchanged lines
The volume of distribution and steady-state clearance increased with body weight; however, the expected change in exposure does not warrant a dosage modification.
LN
LN and Childhood-Onset INS
The population pharmacokinetic analysis of GAZYVA showed thatdid creatininenot clearanceidentify (CLcr) (median [range] 108 [28.9 - 282 mL/min] in LN and 136 [62.3 - 346 mL/min] in childhood-onset INS) doesas nota affectsignificant covariate on the pharmacokinetics inof patients with LN or childhood-onset INS. The pharmacokinetics of obinutuzumab in patients with mild or moderate renal impairment were similar to those in patients with normal kidney function. The safety and efficacy of GAZYVA in patients with severe renal impairment has not been formally studied.
12.6 Immunogenicity
2 unchanged lines
In GAZYVA-treated patients in the LN studies, a total of 12 out of 200 (6%) had at least one ADA-positive sample recorded at any time during the studies. Six (3%) subjects had ADA-positive samples recorded at baseline in which two patients remained ADA-positive throughout the studies, one patient had a single post-baseline sample that was ADA-positive, and three patients had post-baseline samples that were all ADA-negative. Six (3%) patients with ADA-negative samples at baseline had a positive ADA titer post-baseline (treatment-induced ADA). None of the 12 patients with positive ADA titers at any time during the treatment period experienced an IRR or hypersensitivity reaction during the studies. Neutralizing activity of anti-GAZYVA antibodies was not assessed.
Because of the low occurrence of anti-drug antibodies in these studies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety and/or effectiveness of GAZYVA is unknown.
There is insufficient information to characterize the anti-GAZYVA antibody response in patients with childhood-onset INS.

Clinical studies

Changed933 words added, 11 removed
6 unchanged lines
In the Stage 2 analysis of CLL11, the median PFS was 26.7 months in the GAZYVA arm and 14.9 months in the rituximab product arm with a median observation time of 18.7 months (HR: 0.42, 95% CI: 0.33-0.54, p-value < 0.0001). These results were assessed by independent review and are consistent with investigator-assessed PFS. Minimal residual disease (MRD) was evaluated using allele-specific oligonucleotide polymerase chain reaction (ASO-PCR). The cutoff for a negative status was one CLL cell per 104 leukocytes in the sample (i.e., an MRD value of < 10-4 was considered negative). Among patients who achieved complete response (CR) and complete response with incomplete marrow recovery (CRi; 94 patients in the GAZYVA arm and 34 patients in the rituximab product arm), 18 patients (19%) had negative MRD in the bone marrow in the GAZYVA arm compared to 2 patients (6%) in the rituximab product arm. Out of the patients who achieved CR and CRi, 39 patients (41%) in the GAZYVA arm, and 4 patients (12%) in the rituximab product arm were MRD negative in peripheral blood samples collected at least 3 months after the end of treatment.
Efficacy results are shown in Table 1618 and Figures 1 and 2.
Table 1618 Efficacy Results from CLL11
Endpoint | Stage 1 of CLL11 | Stage 2 of CLL11
18 unchanged lines
The major efficacy outcome measure was PFS as determined by an independent review committee (IRC). At the time of the primary analysis, median observation time was 21.1 months. The median PFS in the bendamustine arm was 13.8 months. Median PFS was not reached in the GAZYVA plus bendamustine arm (PFS HR = 0.48, 95% CI: 0.34-0.68; stratified log-rank test p-value < 0.0001). The investigator assessed PFS result was consistent with the IRC-assessed PFS. The median investigator-assessed PFS in the bendamustine arm was 13.7 months and the median in the GAZYVA containing arm was 29.2 months (PFS HR = 0.48, 95% CI: 0.35-0.67; stratified log-rank test p-value < 0.0001).
Efficacy results are summarized in Table 1719. The Kaplan-Meier curve for IRC-PFS is shown in Figure 3.
Table 1719 Primary Analysis Efficacy Results from GADOLIN ,
Endpoint | GADOLIN
16 unchanged lines
Patients had a median age of 59 years, 81% were White and 53% were female; 7% had Stage II, 35% had Stage III, and 56% had Stage IV disease, with 44% having bulky disease (≥ 7 cm) overall; 79% had a FLIPI score of > 2; and 97% had an ECOG performance status of 0–1. The chemotherapy was bendamustine in 57%, CHOP in 33%, and CVP in 10% of patients.
Efficacy was based on PFS per IRC, with a median observation time of 38 months. Upon interim analysis, the risk of progression or death was significantly reduced in the GAZYVA containing arm compared to the rituximab product containing arm (Table 1820). Kaplan-Meier curves for PFS are shown in Figure 5. Overall response and complete remission rates were similar.
Table 1820 Efficacy in Previously Untreated Follicular Lymphoma (GALLIUM)
Endpoint per IRC | GAZYVA + chemotherapy followed by GAZYVA monotherapy n = 601 | Rituximab product + chemotherapy followed by rituximab product monotherapy n = 601
8 unchanged lines
Patients with estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2 or in need of dialysis or transplantation, with sclerosis in > 50% of glomeruli on kidney biopsy, presence of rapidly progressive glomerulonephritis, evidence of active infection, receipt of anti-CD20 therapy < 9 months before or during screening, or receipt of cyclophosphamide, tacrolimus, ciclosporin, or voclosporin within 2 months of or during screening were excluded.
Patients were randomized 1:1 to receive GAZYVA 1,000 mg (N=135) or placebo (N=136) intravenously, in combination with MMF 2-2.5 g/day and a tapering course of corticosteroids and were evaluated over 76 weeks. Patients randomized to receive GAZYVA were further randomized in a 1:1 ratio to receive either GAZYVA 1,000 mg IV on Day 1, Weeks 2, 24, 26, 50, and 52 (Arm 1), or GAZYVA 1,000 mg IV on Day 1, Weeks 2, 24, 26, and 52 (Arm 2). The totality of the GAZYVA efficacy data combining both treatment arms is shown in Table 1921.
All patients received oral prednisone 0.5 mg/kg/day (maximum 60 mg/day) and remained at this dose until Week 2. Beginning on Day 15, prednisone was tapered to achieve a target dose of 5 mg/day by Week 24. Prednisone was maintained at a low dose (5 mg/day) from Week 24 until Week 80.
3 unchanged lines
Key secondary endpoint measures included: proportion of patients who achieved CRR with successful prednisone taper at Week 76 (defined as achievement of CRR at Week 76 without receiving prednisone > 7.5 mg/day or equivalent from Week 64 through Week 76), proportion of patients who achieved a proteinuric response at Week 76 (defined as achievement of UPCR < 0.8g/g and no occurrence of the following intercurrent events: rescue therapy, treatment failure, death or early study withdrawal) and proportion of patients who experience "renal-related events or deaths" through Week 76 (defined as occurrence of death, treatment failure, ≥ 50% increase in UPCR to a value ≥ 3 g/g and/or ≥ 30% decrease in eGFR to < 60 ml/min/1.73 m2).
The proportion of patients achieving CRR at Week 76 was significantly greater in patients treated with GAZYVA in combination with standard therapy compared to patients who received placebo plus standard therapy. There were also a higher proportion of patients who achieved CRR with successful prednisone taper at Week 76 and proteinuric response at Week 76 in the GAZYVA plus standard therapy arm compared to the placebo plus standard therapy arm (see Table 1921).
In the REGENCY study, patients who received GAZYVA were less likely to experience the outcome of "renal-related event or death" compared with placebo. Fewer patients in the GAZYVA arm experienced worsening kidney function or doubling of serum creatinine (see Table 2022).
Table 1921 Summary of Efficacy Results in Adult Patients with Active Lupus Nephritis (REGENCY Study)
| GAZYVA + standard therapy (N=135) | Placebo + standard therapy (N=136)
14 unchanged lines
p-value | 0.0227
Table 2022 Renal-Related Event or Death in Adult Patients with Active Lupus Nephritis (REGENCY Study) by Week 76
| Week 0-76 | Hazard Ratio (HR) vs. Placebo (95% CI) Week 76
18 unchanged lines
Figure 6 Forest Plot of CRR at Week 76 on Baseline Disease Characteristics, Efficacy-Evaluable Patients
14.4 Childhood-Onset Idiopathic Nephrotic Syndrome
Study Design and Population
The efficacy and safety of GAZYVA were evaluated in INSHORE (NCT05627557), a Phase III, randomized, controlled, open-label, multicenter study in 85 patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS).
Frequently relapsing nephrotic syndrome (FRNS) was defined as two or more relapses in the first 6 months after disease onset (or after remission of the initial episode) or three or more relapses per 12 months thereafter. Steroid dependent nephrotic syndrome (SDNS) was defined as two consecutive relapses while on prednisone or prednisolone or within 14-15 days of prednisone or prednisolone discontinuation.
Patients had to be diagnosed before the age of 18 years, have a normal estimated glomerular filtration rate (eGFR) for age, and be in complete remission at study entry, as defined by the absence of edema, a urine protein-to-creatinine ratio (UPCR) of 0.2 g/g or less at screening, and trace or negative urine dipstick on 3 consecutive days within a week prior to randomization. Patients had to have had at least one relapse in the 6 months before screening.
Patients were excluded if they had secondary, steroid resistant, or genetic causes of nephrotic syndrome, treatment failure while receiving mycophenolate mofetil (MMF) (2 or more relapses in a 6 month period), received immunosuppressive medications other than MMF or oral corticosteroids within 2 months prior to randomization, or received biologic B cell-depleting therapy within 9 months prior to baseline. Patients with an active infection, or history of severe allergic or anaphylactic reactions to monoclonal antibodies were also excluded.
A total of 85 patients were randomized 1:1 to intravenous GAZYVA 1,000 mg (or 20 mg/kg if weighing less than 45 kg) on Day 1, Day 15, Week 24, and Week 26, or oral MMF titrated to a target dose of 1200 mg/m2/day divided in two doses (maximum 2,000 mg/day) by Week 4. Patients receiving GAZYVA received premedication with methylprednisolone 80 mg IV (or 1.5 mg/kg if less than 45 kg), acetaminophen/paracetamol 15 mg/kg orally (PO) (maximum dose 1,000 mg) and diphenhydramine 0.5 to 1 mg/kg (maximum dose 50 mg) orally or intravenous equivalent.
Patients who were receiving oral prednisone (or prednisolone equivalent) at randomization were tapered off steroids by Weeks 4−6 (and no later than Week 8) and were to remain off steroids to Week 52.
At baseline, the median age of patients was 9 years (range 2 to 22 years), 64% were 2 years to less than 12 years of age, 65% were male, median disease duration was 46 months, 25% were Hispanic or Latino, 27 % were Asian, 14% were Black or African American, and 55% were White. The mean eGFR was 171 mL/min/1.73 m2, mean UPCR was 0.05 g/g, 45% had FRNS, and 55% had SDNS.
A total of 75% had received prior immunosuppressive therapy other than steroids for INS and 85% were receiving glucocorticoids at baseline. Of the 85 patients, 1 (2%) in the GAZYVA arm and 9 (22%) in the MMF arm discontinued their randomized treatment during the 52-week treatment period.
The primary endpoint was the proportion of patients who did not relapse after Week 8 and were in complete remission at one year, defined as first morning void UPCR ≤ 0.2 g/g at Week 52. Relapse was defined as any of the following: (1) UPCR ≥ 2 g/g, or (2) 3 consecutive daily (home-monitoring) urine dipstick readings of 3+ proteinuria and UPCR > 0.2 g/g in the last of those three urines, or (3) urine dipstick reading of 3+ proteinuria on any single day accompanied by edema and most recent UPCR > 0.2 g/g. In addition, patients were non-responders if they had (1) used systemic corticosteroids for > 14 days in a 30 day period (after Week 8), (2) initiated rescue therapy other than systemic corticosteroids prior to 52 weeks, (3) died prior to 52 weeks, (4) missing UPCR assessments at Week 52.
Efficacy Results
The proportion of patients who did not relapse after Week 8 and were in complete remission at Week 52 was significantly greater (95%) in the GAZYVA as compared to the MMF arm (73%) (see Table 23). Key secondary outcome measures are shown in Table 23.
Table 23 Summary of Efficacy in Patients with Childhood-Onset Idiopathic Nephrotic Syndrome (INSHORE study)
| GAZYVA (N=44) | MMF (N=41)
CI: confidence interval; PY: patient years; UPCR: urine protein to creatinine ratio; INS, idiopathic nephrotic syndrome.
Primary endpoint
Proportion without relapse , after Week 8 and were in complete remission at Week 52, number of patients (%) | 42 (95%) | 30 (73%)
Adjusted difference (95% CI) | 22 (6, 38)
p-value | 0.004
Components of Primary Endpoint, n (%) | |
UPCR of 0.2 or less at Week 52 | 43 (98%) | 40 (98%)
No relapsea after week 8 | 44 (100%) | 32 (78%)
No systemic corticosteroids use after Week 8 | 43 (98%) | 30 (73%)
No use of rescue medication for INS (other than systemic corticosteroids) prior to week 52 | 44 (100%) | 32 (78%)
Key secondary endpoints
Number of patients with first relapse , (event rate per 100 PY) | 4 (7) | 15 (33)
Hazard ratio (95% CI) | 0.25 (0.08, 0.75)
p-value | 0.007
Total number of relapses from randomization to Week 52 | 4 | 24
Adjusted rate ratio (95% CI) | 0.16 (0.05, 0.44)
p-value | 0.0005

Untitled section

Changed1 word added, 1 removed
1 unchanged line
Manufactured by: Genentech, Inc. A Member of the Roche Group 1 DNA Way South San Francisco, CA 94080-4990 U.S. License No. 1048
GAZYVA is a registered trademark of Genentech, Inc. © 20252026 Genentech, Inc.

Unchanged: Boxed warning, Dosage forms and strengths, Contraindications, Overdosage, Description, Nonclinical toxicology, How supplied, Patient counseling information, PRINCIPAL DISPLAY PANEL - 40 mL Vial Carton.

Every version

20 versions of set df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.